R. Somwar

M. Ladanyi, C. Rudin, M. Kris, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Amanda R. Kulick, M. Ladanyi, M. Berger, 2019, Nature Medicine.

Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation

Jessica L. Davis, M. Ladanyi, R. Somwar, 2022, Cold Spring Harbor Molecular Case Studies.

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

M. Ladanyi, M. Berger, M. Kris, 2018, Clinical Cancer Research.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

M. Ladanyi, C. Sima, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

D. Pe’er, M. Ladanyi, M. Kris, 2020, Clinical Cancer Research.

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

R. Somwar, W. Lockwood, Yankuan T Chen, 2022, Cancers.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

M. Ladanyi, A. Drilon, M. Kris, 2020, Clinical Cancer Research.

Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR‐Mediated Lung Tumorigenesis

Bradley P. Coe, B. Coe, S. Lam, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition

M. Ladanyi, A. Drilon, R. Somwar, 2017, Clinical Cancer Research.

Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma

N. Altorki, R. Somwar, N. Narula, 2016, Oncotarget.

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

M. Ladanyi, A. Drilon, M. Kris, 2015, Clinical Cancer Research.

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

M. Ladanyi, A. Drilon, Shunqi Yan, 2016, Clinical Cancer Research.

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

W. Pao, K. Politi, R. Somwar, 2007, PLoS medicine.

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

M. Ladanyi, A. Drilon, E. Cheng, 2020, Disease Models & Mechanisms.

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

Erwin G. Van Meir, M. Ladanyi, R. Somwar, 2018, Clinical Cancer Research.

Identification and Preliminary Characterization of Novel Small Molecules That Inhibit Growth of Human Lung Adenocarcinoma Cells

H. Varmus, R. Somwar, David Shum, 2009, Journal of biomolecular screening.

Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non

N. Socci, A. Viale, M. Ladanyi, 2011 .

NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors

M. Ladanyi, M. Kris, W. Pao, 2006 .

Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers.

M. Ladanyi, M. Kris, S. Toyooka, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

M. Ladanyi, A. Drilon, C. Rudin, 2016, The Lancet. Oncology.

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

M. Ladanyi, A. Drilon, C. Rudin, 2016, The Lancet. Oncology.

An Inhibitor of p38 Mitogen-activated Protein Kinase Prevents Insulin-stimulated Glucose Transport but Not Glucose Transporter Translocation in 3T3-L1 Adipocytes and L6 Myotubes*

R. Somwar, A. Klip, G. Sweeney, 1999, The Journal of Biological Chemistry.

Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines

Chris Sander, Erik Larsson, David Shum, 2011, Proceedings of the National Academy of Sciences.

Activation of the glucose transporter GLUT4 by insulin.

R. Somwar, A. Klip, G. Sweeney, 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.

B. Taylor, M. Ladanyi, J. Reis-Filho, 2016, Cancer research.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, JCO precision oncology.

Intracellular Delivery of Phosphatidylinositol (3,4,5)-Trisphosphate Causes Incorporation of Glucose Transporter 4 into the Plasma Membrane of Muscle and Fat Cells without Increasing Glucose Uptake*

L. Foster, G. Prestwich, R. Somwar, 2004, Journal of Biological Chemistry.

Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport.

R. Somwar, A. Marette, A. Klip, 2000, Diabetes.

Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.

H. Varmus, G. Morin, S. Dixon, 2022, Cell reports.

A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1

H. Varmus, G. Morin, S. Dixon, 2021, bioRxiv.

Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein

M. Ladanyi, R. Somwar, Hong-Jun Kang, 2022, Frontiers in Cell and Developmental Biology.

Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor

M. Ladanyi, D. Drewry, R. Somwar, 2022, Oncogenesis.

Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

M. Ladanyi, C. Pratilas, R. Somwar, 2020, Clinical Cancer Research.

Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells

R. Somwar, G. Sweeney, R. Ceddia, 2004, Diabetologia.

GLUT 4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells : potential activation of GLUT 4 via p 38 mitogen-activated protein kinase

R. Somwar, A. Klip, G. Sweeney, 2022 .

MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion-positive lung cancer.

M. Ladanyi, A. Drilon, Gregory Riely, 2022, Molecular cancer research : MCR.

P1.14-50 A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma

M. Ladanyi, A. Drilon, M. Kris, 2019, Journal of Thoracic Oncology.

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors

Kristen L Jones, S. Kaech, R. Somwar, 2021, Molecular Cancer Therapeutics.

ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development.

M. Ladanyi, R. Somwar, A. Drilon, 2021, JCO oncology practice.

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

M. Ladanyi, A. Drilon, R. Somwar, 2020, Communications Biology.

Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.

M. Ladanyi, G. Ganji, R. Somwar, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

M. Ladanyi, C. Pratilas, R. Somwar, 2020, bioRxiv.

MET inhibitor resistance in patients with MET exon 14-altered lung cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2019, Journal of Clinical Oncology.

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.

D. Pe’er, M. Ladanyi, M. Kris, 2019, Journal of Clinical Oncology.

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Amanda R. Kulick, M. Ladanyi, M. Berger, 2019, Nature Network Boston.

Novel patient-derived models of DSRCT enable validation of ERBB signaling as a potential therapeutic vulnerability.

M. Ladanyi, C. Pratilas, R. Somwar, 2021, Disease Models & Mechanisms.

Protein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts

J. Woodgett, R. Somwar, A. Klip, 1999, Molecular and Cellular Biology.